New malaria parasite mutations in Uganda threaten Africa's primary treatment

Researchers at Brown University have identified new genetic mutations in malaria parasites from Uganda that show significantly decreased susceptibility to artemisinin-based combination therapies (ACTs), the most widely used malaria treatments in Africa and the United States. By sequencing whole genomes from hundreds of infected patients, scientists discovered a cluster of genetic variants associated with drug resistance. These findings raise serious concerns about the effectiveness of current malaria therapies across Africa, potentially complicating treatment strategies in regions already struggling with the disease. Understanding these mutations is crucial for developing new antimalarial drugs and maintaining treatment efficacy for vulnerable populations.